Commission Implementing Regulation (EU) 2025/2081
This regulation imposes definitive anti-dumping duties on imports of steel track shoes originating from China. The standard anti-dumping duty is 62.5%. Some types of steel track shoes are excluded from this standard duty, based on dimentions. The regulation outlines calculation methods of the anti-dumping duty for steel track shoes assembled in track chains. It mandates the definitive collection of provisional duties imposed earlier, but without retroactive application beyond the provisional measures.
Commission Implementing Regulation (EU) 2025/2074
This regulation grants Union authorization to B. Braun Medical AG for the biocidal product family called ‘B. Braun Medical Propanol Family’. The authorization covers product-types 1, 2, and 4, including human hygiene, disinfectants for non-direct human/animal use, and applications for food/feed areas. The active substances are propan-1-ol and propan-2-ol. The authorization is valid from November 9, 2025, until October 31, 2035. As part of authorization, the holder must conduct a long-term storage stability test and submit the results to the Agency by September 9, 2026. Annex II provides a summary of the biocidal product characteristics for the ‘B. Braun Medical Propanol Family’, including administrative information, product family composition, hazard and precautionary statements, authorised uses, and general directions for use.
Regulation (EU) 2025/2088
Regulation (EU) 2025/2088 modernises reporting requirements in the financial sector and streamlines investment support programs. It focuses on reducing administrative burdens while ensuring effective monitoring. The ESAs (EBA, EIOPA, ESMA), ESRB, SRB, ECB, and AMLA must share information with other relevant authorities. Opinions on legislative acts can be provided by the ESAs. An integrated reporting system is planned, and a single contact point will be established for entities to report redundant requirements. Data re-use for research and innovation is permitted. The frequency of InvestEU reporting is changed from biannual to annual.
Commission Regulation (EU) 2025/2084
This regulation amends existing rules on quillaia extract (E 999) as a food additive. It expands the permitted uses to include flavourings and food supplements, excluding those for infants and young children. Updated specifications for quillaia extract are introduced, including stricter limits for heavy metals (arsenic, lead, mercury), new limits for cadmium and calcium oxalate, and microbiological criteria. Existing quillaia extract that was lawfully placed on the market before 9 May 2026 may continue to be used until stocks are exhausted.
Decision No 3/2025 of the EU-Ukraine Association Committee in Trade Configuration
This decision aims to deepen trade liberalization between the EU and Ukraine by reducing or eliminating customs duties on a range of goods. It introduces a new Annex (I-E) to the Association Agreement, which outlines specific commitments regarding the reduction or elimination of customs duties. This annex supersedes the original customs duty rates set out in Annex I-A of the Association Agreement. This new annex broadens the scope of duty reductions and eliminations. Ukraine must align its legislation with specific EU legal acts related to production standards by the end of 2028. Either party can take safeguard measures if serious difficulties arise due to increased imports.
Review of each of legal acts published today:
Commission Implementing Regulation (EU) 2025/2086 of 17 October 2025 laying down, pursuant to Regulation (EU) 2021/2282 on health technology assessment, procedural rules for the interaction during, exchange of information on, and participation in, the preparation and update of joint clinical assessments of medical devices and in vitro diagnostic medical devices at Union level, as well as templates for those joint clinical assessments
Okay, I can help you with that. Here’s a breakdown of Commission Implementing Regulation (EU) 2025/2086:
**1. Essence of the Act:**
This regulation establishes the procedural framework for how the Member State Coordination Group on Health Technology Assessment (Coordination Group), the European Commission, health technology developers, notified bodies, expert panels, individual experts, and Member States will interact and exchange information during the preparation, update, and execution of joint clinical assessments (JCAs) for medical devices and in vitro diagnostic medical devices at the EU level. It also sets out the templates to be used for these JCAs. The goal is to streamline the assessment process, avoid duplication of effort, and ensure that high-quality, consistent clinical assessments are available across the EU for these types of devices.
**2. Structure and Main Provisions:**
The regulation is structured around key stages of the JCA process for medical devices, focusing on how different parties interact and what information is exchanged.
* **Information Exchange:** It details how the HTA secretariat (acting for the Coordination Group) will interact with notified bodies and expert panels regarding the selection of medical devices for JCAs. This includes timelines for providing information and the types of information to be shared.
* **Interaction with Stakeholders:** It outlines the procedures for interaction with health technology developers, individual experts, patients, and Member States during JCAs and their updates, including timelines and methods for providing input.
* **Selection of Experts:** It sets out rules for selecting individual experts to participate in JCAs, emphasizing the need for diverse expertise and the management of conflicts of interest.
* **Assessment Scope:** It describes the process for developing and finalizing the assessment scope for each JCA, including the roles of the assessor, co-assessor, JCA Subgroup, and health technology developer.
* **Dossier Submission:** It specifies the format and deadlines for health technology developers to submit dossiers containing the information, data, analyses, and other evidence needed for JCAs. Annexes I and II provide templates for these dossiers for medical devices and in vitro diagnostic medical devices, respectively.
* **JCA Reports:** It provides templates for the joint clinical assessment reports (Annexes III and IV) and summary reports (Annex V), ensuring consistency in the presentation of findings.
* **Re-initiation and Updates:** It establishes procedures and timelines for re-initiating JCAs that have been discontinued and for updating existing JCAs when new evidence becomes available.
* **Confidentiality:** It addresses the handling of confidential information submitted by health technology developers, balancing transparency with the protection of commercially sensitive data.
* **Personal Data Processing:** It includes provisions on the processing of personal data related to individual experts and other stakeholders involved in JCAs, in compliance with EU data protection regulations.
**3. Main Provisions Important for Use:**
* **Timelines for Information Submission:** Health technology developers and notified bodies need to be aware of the strict deadlines for submitting information to the HTA secretariat. Missing these deadlines could impact the JCA process.
* **Dossier Templates:** Health technology developers must use the specified templates (Annexes I and II) when preparing their dossiers for JCAs. Deviating from these templates could lead to delays or rejection of the submission.
* **Assessment Scope:** Health technology developers should pay close attention to the assessment scope defined for each JCA, as this will determine the focus of the assessment and the evidence required.
* **Confidentiality Requests:** Health technology developers must clearly identify any information they consider confidential and provide justification for this designation. The Commission will ultimately decide whether to redact this information from published reports.
* **Involvement of Experts and Stakeholders:** The regulation emphasizes the importance of involving individual experts, patients, and other stakeholders in the JCA process. Health technology developers should be prepared to address any input received from these parties.
* **Updates of Joint Clinical Assessments:** The health technology developer should inform the Coordination Group of the need for an update and additional evidence for further assessment becomes available.
I hope this comprehensive description is helpful!
Commission Implementing Regulation (EU) 2025/2081 of 17 October 2025 imposing a definitive anti-dumping duty and definitively collecting the provisional duty imposed on imports of steel track shoes originating in the People’s Republic of China
This is a Commission Implementing Regulation (EU) 2025/2081 imposing a definitive anti-dumping duty on imports of steel track shoes originating in the People’s Republic of China. This regulation follows an anti-dumping investigation initiated in August 2024 after a complaint lodged by Duferco Travi e Profilati S.p.A. The Commission had previously imposed provisional anti-dumping duties in April 2025.
The regulation consists of several sections detailing the procedure, product definition, dumping assessment, injury analysis, causation, level of measures, and Union interest. It confirms the imposition of a definitive anti-dumping duty of 62.5% on all imports of steel track shoes originating in China, with certain exceptions for specific types of steel track shoes. The regulation also addresses the application of duties to steel track shoes assembled in track chains and clarifies how the duty should be calculated in such cases.
Key provisions include the imposition of a 62.5% anti-dumping duty on steel track shoes from China, with a specific exclusion for steel track shoes exceeding certain dimensions and lacking grousers. For assembled track chains, the value of the steel track shoes must be declared, and if it’s below 31% of the chain’s value or not declared, the duty applies to 31% of the chain’s price. The regulation also mandates the definitive collection of provisional duties imposed earlier, but without retroactive application beyond the provisional measures.
Commission Implementing Regulation (EU) 2025/2074 of 16 October 2025 granting a Union authorisation for the biocidal product family B. Braun Medical Propanol Family in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
This is a Commission Implementing Regulation (EU) 2025/2074, which grants a Union authorisation for the biocidal product family named ‘B. Braun Medical Propanol Family’. The product family is authorized for product-types 1, 2 and 4, which include human hygiene, disinfectants not for direct human/animal use, and food/feed area applications. The active substances in this product family are propan-1-ol and propan-2-ol. The authorisation is valid from November 9, 2025, until October 31, 2035.
The regulation consists of two articles and two annexes. Article 1 grants the Union authorisation to B. Braun Medical AG for the biocidal product family ‘B. Braun Medical Propanol Family’, sets the authorisation number and specifies the period of validity. Article 2 states the date of entry into force of the regulation. Annex I outlines the terms and conditions of the authorisation, including the requirement for the authorisation holder to conduct a long-term storage stability test and submit the results to the Agency by September 9, 2026. Annex II provides a summary of the biocidal product characteristics for the ‘B. Braun Medical Propanol Family’, including administrative information, product family composition, hazard and precautionary statements, authorised uses, and general directions for use.
The most important provision is the granting of the Union authorisation itself, which allows B. Braun Medical AG to make available on the market and use the biocidal product family ‘B. Braun Medical Propanol Family’ within the European Union, subject to the conditions specified in the annexes. The requirement to conduct a long-term storage stability test and submit the results is also important, as it ensures the continued efficacy and safety of the product over its authorised lifespan.
Regulation (EU) 2025/2088 of the European Parliament and of the Council of 8 October 2025 amending Regulations (EU) No 1092/2010, (EU) No 1093/2010, (EU) No 1094/2010, (EU) No 1095/2010, (EU) No 806/2014, (EU) 2021/523 and (EU) 2024/1620 as regards certain reporting requirements in the fields of financial services and investment support (Text with EEA relevance)
Regulation (EU) 2025/2088 aims to streamline and modernise reporting requirements within the financial sector and for investment support programs. It focuses on reducing administrative burdens and avoiding duplication of reporting for both authorities and entities, while ensuring the effective monitoring and enforcement of Union law. The regulation facilitates better information sharing among various EU and national authorities, and promotes the reuse of data for research and innovation purposes. Additionally, it adjusts the frequency of reporting for the InvestEU Programme to reduce the burden on implementing partners.
The Regulation amends several key pieces of legislation, including Regulations (EU) No 1092/2010 (ESRB), (EU) No 1093/2010 (EBA), (EU) No 1094/2010 (EIOPA), (EU) No 1095/2010 (ESMA), (EU) No 806/2014 (SRB), (EU) 2021/523 (InvestEU) and (EU) 2024/1620 (AMLA).
**Key changes and provisions include:**
* **Enhanced Information Sharing:** The ESAs (EBA, EIOPA, ESMA), ESRB, SRB, ECB, and AMLA are required to share information with other relevant authorities upon request, provided the requesting authority has the legal basis to obtain such information. They should generally request information from other authorities before requesting it directly from financial institutions, adhering to the “report once” principle.
* **Opinions on Legislative Acts:** The ESAs can provide opinions on the functioning of existing legislative acts, including the removal of redundant reporting requirements.
* **Review of Technical Standards:** The ESAs are tasked with reviewing and proposing amendments to regulatory and implementing technical standards to remove redundancies, ensure proportionality, and address regulatory gaps.
* **Integrated Reporting System:** The ESAs, through the Joint Committee, are to prepare a report by November 11, 2030, presenting options for enhancing the efficiency of supervisory data collection, including a feasibility study and roadmap for a cross-sectoral integrated reporting system.
* **Single Contact Point:** A permanent single contact point is to be established for entities to report duplicative, redundant, or obsolete reporting requirements.
* **Data Re-use for Research and Innovation:** Authorities can grant access to anonymised information for re-use by financial institutions, researchers, and other entities for research and innovation purposes, subject to strict conditions to protect confidentiality and data privacy.
* **InvestEU Reporting:** The frequency of reporting on the InvestEU Programme is changed from biannual to annual, reducing the administrative burden on implementing partners.
**Main provisions that may be the most important for its use:**
* **Article 35a in Regulations (EU) No 1093/2010, No 1094/2010 and No 1095/2010:** These articles detail the conditions and procedures for the exchange of information between the ESAs, the ECB, and other authorities, including the obligation to request information from other authorities before directly from financial institutions.
* **Article 35b in Regulations (EU) No 1093/2010 and No 1094/2010 and No 1095/2010:** This article mandates the preparation of a report on options for enhancing supervisory data collection and the establishment of a single contact point for reporting redundancies.
* **Article 31a in Regulation (EU) No 806/2014:** This article outlines the information-sharing requirements for the Single Resolution Board (SRB) with other authorities.
* **Article 6 amending Article 28 of Regulation (EU) 2021/523:** This article changes the reporting frequency for the InvestEU Programme from biannual to annual.
* **Article 92a in Regulation (EU) 2024/1620:** This article specifies the conditions for information exchange by the Authority for Anti-Money Laundering and Countering the Financing of Terrorism (AMLA).
Commission Regulation (EU) 2025/2084 of 17 October 2025 amending Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the use of quillaia extract (E 999) and Commission Regulation (EU) No 231/2012 as regards the specifications for quillaia extract (E 999)
This is Commission Regulation (EU) 2025/2084 amending Regulation (EC) No 1333/2008 and Regulation (EU) No 231/2012 regarding the use and specifications of quillaia extract (E 999) as a food additive. The regulation expands the permitted uses of quillaia extract to include flavourings and food supplements (excluding those for infants and young children) and updates the specifications for quillaia extract to align with current safety standards and technical advancements. These changes are based on scientific opinions from the European Food Safety Authority (EFSA).
The Regulation consists of 5 articles and 3 annexes.
* **Article 1** amends Annex II to Regulation (EC) No 1333/2008, updating the permitted uses and maximum levels of quillaia extract in flavored drinks and cider/perry, and adding new uses in solid and liquid food supplements (excluding those for infants and young children). The maximum levels are expressed as saponins.
* **Article 2** amends Annex III to Regulation (EC) No 1333/2008, adding quillaia extract to the list of food additives allowed in flavourings used in specific food categories, with maximum use levels specified for each category, expressed as saponins.
* **Article 3** amends the Annex to Regulation (EU) No 231/2012, replacing the existing specifications for quillaia extract with updated ones. These include a more detailed definition, the inclusion of the CAS number, a minimum saponin content, reduced limits for toxic elements (arsenic, lead, mercury), and new limits for cadmium and calcium oxalate. It also introduces microbiological criteria.
* **Article 4** provides transitional measures, allowing the continued use of quillaia extract that was lawfully placed on the market before 9 May 2026, until stocks are exhausted. Foods containing this quillaia extract can be sold until their date of minimum durability or use-by date.
* **Article 5** specifies the entry into force of the Regulation, with Article 3 (the updated specifications) applying from 9 May 2026.
The most important provisions for practical use are:
1. **Expanded Use:** The authorization of quillaia extract (E 999) for use as an emulsifier in flavourings and in solid and liquid food supplements (excluding those for infants and young children) broadens its application in the food industry.
2. **Updated Specifications:** The revised specifications for quillaia extract (E 999) include stricter limits for heavy metals and the introduction of limits for cadmium and calcium oxalate. These changes aim to ensure a higher level of purity and safety for consumers. The inclusion of microbiological criteria further enhances the quality control of this food additive.
3. **Saponin Basis:** The expression of maximum use levels on a saponin basis provides a more accurate and consistent measure for the application of quillaia extract, aligning with the Authority’s recommendations and ensuring that the functional component is appropriately controlled.
4. **Transitional Measures:** The transitional provisions in Article 4 allow food business operators sufficient time to adapt to the new regulations, minimizing disruption to the market and preventing unnecessary waste of existing stocks.
Decision No 3/2025 of the EU-Ukraine Association Committee in Trade Configuration of 14 October 2025 on the reduction and elimination of customs duties pursuant to Article 29(4) of the Association Agreement between the European Union and the European Atomic Energy Community and their Member States, of the one part, and Ukraine, of the other part [2025/2130]
Okay, I can help you with that. Here’s a breakdown of Decision No 3/2025 of the EU-Ukraine Association Committee in Trade Configuration:
**1. Essence of the Act:**
This decision aims to deepen trade liberalization between the European Union and Ukraine by reducing or eliminating customs duties on a range of goods. It introduces a new Annex (I-E) to the existing Association Agreement, which outlines specific commitments from both parties regarding the reduction or elimination of customs duties. This decision reflects the increasing trade between the EU and Ukraine and seeks to further integrate Ukraine into the EU internal market, especially considering Ukraine’s ongoing accession negotiations with the EU.
**2. Structure and Main Provisions:**
The decision is structured around the adoption of a new Annex I-E to the Association Agreement. Here’s a breakdown:
* **Article 1:** Formally inserts Annex I-E into the Association Agreement. This annex includes appendices detailing the specific commitments for duty reduction and elimination.
* **Article 2:** Addresses the implementation of tariff rate quotas (TRQs) for 2025, specifying that the quantities will be seven-twelfths of the revised TRQs listed in Annex I-E.
* **Article 3:** Mandates a review in 2028 to assess the agreed-upon reductions and eliminations of customs duties, considering the progress of Ukraine’s EU accession and potentially leading to further liberalization.
* **Article 4:** States that the decision is equally authentic in all official languages of the EU, including Ukrainian.
* **Article 5:** Sets the entry into force of the decision as the fifteenth day following its adoption.
**Annex I-E** contains the core commitments:
* **Article 1:** Stipulates that each party will reduce or eliminate customs duties on originating goods from the other party, according to Appendix A. This appendix supersedes the original duty rates in Annex I-A. It also clarifies that if Appendix A is suspended, the original rates in Annex I-A will temporarily apply.
* **Article 2:** Requires Ukraine to align its legislation with specific EU legal acts related to production standards by the end of 2028. It includes reporting obligations for Ukraine, consultation mechanisms if the EU Commission finds Ukraine has not met its obligations, and the possibility for the EU to suspend preferences if alignment is not achieved.
* **Article 3:** Allows either party to take safeguard measures if serious economic, societal, or environmental difficulties arise due to increased imports resulting from the duty reductions or eliminations. It sets out notification and consultation procedures.
**Appendices to Annex I-E:**
* **Appendix A:** Contains detailed tariff schedules for both Ukraine and the EU, listing specific goods and the corresponding base rates, staging categories, and any tariff rate quotas (TRQs). This section outlines which products will have duties reduced or eliminated and the timeline for these changes.
* **Appendix B:** Summarizes the aggregate quantities for the tariff rate quotas (TRQs) mentioned in Appendix A, providing an overview of the total import volumes allowed under these preferential rates.
* **Appendix C:** Lists the specific EU legal acts related to production standards that Ukraine is required to align with. These acts cover a range of areas, including animal welfare, plant protection products, and food and feed safety.
**Main Changes Compared to Previous Versions:**
This decision introduces Annex I-E, which supersedes the original customs duty rates set out in Annex I-A of the Association Agreement. The new annex broadens the scope of duty reductions and eliminations, reflecting the dynamic trade relationship between the EU and Ukraine.
**3. Main Provisions Important for Use:**
* **Tariff Schedules (Appendix A):** Businesses involved in trade between the EU and Ukraine should carefully review the tariff schedules in Appendix A to identify specific changes in customs duties for their products. Understanding the base rates, staging categories, and any applicable TRQs is crucial for planning import/export activities.
* **Production Standards (Article 2 and Appendix C):** Ukrainian producers, especially in the agricultural sector, need to be aware of the EU production standards listed in Appendix C. Compliance with these standards is essential to maintain preferential access to the EU market. The reporting requirements and potential for suspension of preferences outlined in Article 2 are also important to note.
* **Safeguard Measures (Article 3):** Both EU and Ukrainian businesses should be aware of the safeguard measures provision, which could be invoked if increased imports cause significant difficulties in a particular sector or region. Understanding the notification and consultation procedures is important for businesses potentially affected by such measures.
* **Tariff Rate Quotas (TRQs):** The decision makes frequent use of TRQs, which allow a specified quantity of goods to be imported at a reduced or zero tariff rate, while quantities exceeding the quota are subject to a higher tariff.
****
